Vizient (R) is proud to announce that the Vizient Clinical Data Base was recognized by Modern Healthcare as one of the Best in Business of 2025. The entire list of winners can be found in the Jan. 12, ...
Cytovale(R) , a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced that it was ...
Tina Eden, R.N., CEO of Virginia Gay Hospital, and Jacinda Bunch, Ph.D., R.N., assistant professor at the Iowa College of ...
Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...
What antibiotic should I use to treat this patient’s Klebsiella pneumoniae? It’s resistant to carbapenems, and there’s a ...
UNR med students and faculty work to provide free medical services to patients who are uninsured, underinsured or facing ...
First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries– Investigator-Initiated (IIT) funded pancreatic and ...
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has ...
In this conversation, Tina Eden, R.N., CEO of Virginia Gay Hospital, and Jacinda Bunch, Ph.D., R.N., assistant professor at ...
Based on the topline results from HERIZON-GEA-01, Jazz plans to submit a supplemental Biologics License Application in 1H-2026 for zanidatamab in the U.S. as first-line treatment for HER2+ locally ...
Invitation-only working summit convenes FDA, CMS, and industry leaders April 10 in Charlotte, North Carolina. This call ...
Genmab shifts to innovation-led growth with 21% revenue, 52% operating profit, $3.4B cash, Epkinly, Rina-S, and Anthropic AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback